BMO Capital lowered its price target on Abbvie (NYSE: ABBV) to $78.00 (from $81.00) while maintaining an Underperform rating.Analyst Alex ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE